Detalhe da pesquisa
1.
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.
Bioorg Med Chem Lett
; 37: 127846, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571650
2.
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Bioorg Med Chem Lett
; 29(4): 631-637, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30594432
3.
Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Bioorg Med Chem Lett
; 28(19): 3155-3160, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30177375
4.
DOSY NMR for monitoring self aggregation of bifunctional organocatalysts: increasing enantioselectivity with decreasing catalyst concentration.
Org Biomol Chem
; 8(17): 3918-22, 2010 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20623059
5.
Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects.
Sci Rep
; 10(1): 21280, 2020 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33277568